Company Veracyte, Inc.

Equities

VCYT

US92337F1075

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for Veracyte, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Diagnostics & Testing

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
19.45 ^USD	+1.30%		-3.86%	-29.30%

Apr. 15	Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating	MT
Feb. 26	Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating	MT

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.

Number of employees: 815

USD in Million	2022	Weight	2023	Weight	Delta
Diagnostic Products and Biopharmaceutical Services 100.0 %	297	100.0 %	361	100.0 %	+21.76%

USD in Million	2022	Weight	2023	Weight	Delta
United States 92.7 %	263	88.7 %	335	92.7 %	+27.23%
International 7.3 %	34	11.3 %	27	7.3 %	-21.08%

Managers	Title	Age	Since
Marc Stapley CEO	Chief Executive Officer	54	21-05-31
Rebecca Chambers DFI	Director of Finance/CFO	46	21-07-18
Steven French CTO	Chief Tech/Sci/R&D Officer	-	22-06-30
Phillip Febbo CTO	Chief Tech/Sci/R&D Officer	57	23-10-01
Richard T. Kloos CTO	Chief Tech/Sci/R&D Officer	-	12-04-04
Shayla Gorman IRC	Investor Relations Contact	-	22-01-31
Tracy Morris IRO	Public Communications Contact	-	-
John Leite PRN	Corporate Officer/Principal	-	22-08-31
Annie McGuire HRO	Human Resources Officer	44	22-02-27
Robert Brainin PRN	Corporate Officer/Principal	53	21-07-07

Members of the board	Title	Age	Since
Evan Jones BRD	Director/Board Member	67	08-01-31
Robert Epstein CHM	Chairman	69	15-01-11
Karin Eastham BRD	Director/Board Member	74	12-11-30
John Bishop BRD	Director/Board Member	79	14-11-30
Jens Holstein BRD	Director/Board Member	60	20-07-31
Marc Stapley CEO	Chief Executive Officer	54	21-05-31
Eliav Barr BRD	Director/Board Member	-	22-08-08
Muna Bhanji BRD	Director/Board Member	61	21-03-18

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	78,436,369	77,537,934 ( 98.85 %)	0	98.85 %

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 9.482 %	7,118,211	9.482 %	158 M $
Wellington Management Co. LLP 9.416 %	7,068,435	9.416 %	157 M $
ARK Investment Management LLC 9.382 %	7,042,783	9.382 %	156 M $
BlackRock Advisors LLC 8.814 %	6,616,546	8.814 %	147 M $
Dimensional Fund Advisors LP 4.493 %	3,372,703	4.493 %	75 M $
Artisan Partners Holdings LP 4.286 %	3,217,728	4.286 %	71 M $
STATE STREET CORPORATION 4.141 %	3,108,639	4.141 %	69 M $
Nikko Asset Management Americas, Inc. 4.136 %	3,104,676	4.136 %	69 M $
ArrowMark Colorado Holdings LLC 3.353 %	2,517,140	3.353 %	56 M $
Champlain Investment Partners LLC 2.915 %	2,188,260	2.915 %	48 M $

Veracyte, Inc.

6000 Shoreline Court Suite 300

94080, South San Francisco

+650 243 6300

http://www.veracyte.com

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

19.2 USD

Average target price

30.83 USD

Spread / Average Target

+60.59%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Diagnostics & Testing

	1st Jan change	Capi.
VERACYTE, INC.	-29.30%	1.44B
EXACT SCIENCES CORPORATION	-17.60%	11.52B
IOVANCE BIOTHERAPEUTICS, INC.	+39.11%	3.27B
BGI GENOMICS CO., LTD.	-20.67%	2.02B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+11.45%	1.01B
SEEGENE, INC.	-6.33%	719M
CAREDX, INC	-30.75%	418M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-51.02%	339M
CURIOX BIOSYSTEMS CO., LTD	-2.58%	284M
HLB BIOSTEP CO.,LTD.	+25.57%	240M

Bio Diagnostics & Testing